# Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients

> **NCT06388642** · PHASE1,PHASE2 · COMPLETED · sponsor: **Clinuvel Europe Limited** · enrollment: 28 (actual)

## Conditions studied

- Erythropoietic Protoporphyria

## Interventions

- **DRUG:** Afamelanotide 16mg implant

## Key facts

- **NCT ID:** NCT06388642
- **Lead sponsor:** Clinuvel Europe Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-07
- **Primary completion:** 2024-10-28
- **Final completion:** 2025-01-20
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06388642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06388642, "Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06388642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*